One through line with Trump is his frustration with the free press. In his post-2016 news conference, he assailed CNN as ...

Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Both radiotherapy and endocrine therapy are good single-modality options for women 70 years or older with early, favorable ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the ...

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...

Pfizer Inc.'s ( NYSE:PFE) periodic dividend will be increasing on the 7th of March to $0.43, with investors receiving 2.4% ...

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients ...

In this deep dive BioSpace explores the opportunities and challenges presented by the FDA’s accelerated approval program.

2024 was one of the most eventful years for the pharmaceutical, biotech, life sciences and medical marketing industries.

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Pfizer just raised its dividend by 2.4% to $0.43, giving investors something to cheer about despite the stock’s lackluster ...